NASDAQ
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Open
$0.16
Previous Close
$0.15
Day High
$0.17
Day Low
$0.15
52 Week High
$1.50
52 Week Low
$0.14
No price data available for this timeframe.